نتایج جستجو برای: cap oseltamivir

تعداد نتایج: 24776  

2015
Nastaran Khodadad Afagh Moattari Mahmoud Shamsi Shahr Abadi Mohammad Rahim Kadivar Jamal Sarvari Forough Tavakoli Neda Pirbonyeh Amir Emami

BACKGROUND Oseltamivir has been used as a drug of choice for the prophylaxis and treatment of human influenza A(H1N1)pdm09 infection across the world. However, the most frequently identified oseltamivir resistant virus, influenza A(H1N1)pdm09, exhibit the H275Y substitution in NA gene. OBJECTIVES This study aimed to determine the prevalence and phylogenetic relationships of oseltamivir resist...

Journal: :Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010
Wei Liu Fang Tang Zeng-De Li Hong Yang Wu-Chun Cao

tamivir-resistant A (H1N1) infections that were treated with oseltamivir reported a shorter duration of cough; however, no other differences were found. We also compared the proportion of patients who reported fever, cough, sore throat, chills, myalgia or arthralgia, and difficulty breathing. Patients with oseltamivir-resistant A (H1N1) infection that was treated with oseltamivir were less like...

2012
A. C. Hurt K. Hardie N. J. Wilson Y. M. Deng M. Osbourn S. K. Leang R. T. C. Lee P. Iannello N. Gehrig R. Shaw P. Wark N. Caldwell R. C. Givney L. Xue S. Maurer-Stroh D. E. Dwyer B. Wang D. W. Smith A. Levy R. Booy R. Dixit T. Merritt A. Kelso C. Dalton D. Durrheim I. G. Barr

BACKGROUND Oseltamivir resistance in A(H1N1)pdm09 influenza is rare, particularly in untreated community cases. Sustained community transmission has not previously been reported. METHODS Influenza specimens from the Asia-Pacific region were collected through sentinel surveillance, hospital, and general practitioner networks. Clinical and epidemiological information was collected on patients i...

Journal: :British journal of clinical pharmacology 2010
Brian E Davies Pau Aceves Baldó Sian Lennon-Chrimes Mike Brewster

AIM To investigate whether oseltamivir enhances the anticoagulant effect of warfarin and to evaluate any pharmacokinetic (PK) interaction between the agents. METHODS Twenty volunteers (mean age 62 years) receiving daily warfarin and with INR values of 2.0-3.5 during the previous 2 weeks were randomized to concomitant oseltamivir 75 mg twice daily for 4.5 days or warfarin alone in a two-way cr...

Journal: :The Medical journal of Australia 2010
David J Speers Simon H Williams Mary Pinder Harry R Moody Aeron C Hurt David W Smith

After a 10-day course of oral oseltamivir for pandemic (H1N1) 2009 influenza infection, a renal transplant recipient developed rapid-onset severe primary viral pneumonia due to oseltamivir-resistant virus. Respiratory failure progressed despite high-dose oral oseltamivir, nebulised zanamivir and cessation of immunosuppressive medications, but his condition improved with intravenous zanamivir. H...

2010
Zeev Zonis Dan Engelhard Musa Hindiyeh Daniela Ram Michal Mandelboim Ella Mendelson Daniel Glikman

To the Editor: During the spring of 2009, a pandemic influenza A (H1N1) virus emerged and spread globally. Initial testing of the virus found it susceptible to neuraminidase inhibitors and resistant to adamantanes (1,2). As of March 5, 2010, only 264 cases of oseltamivir-resistant pandemic (H1N1) 2009 infection had been reported to the World Health Organization, but the number of cases has been...

2010
Ly Le Eric H. Lee David J. Hardy Thanh N. Truong Klaus Schulten

Oseltamivir (Tamiflu) is currently the frontline antiviral drug employed to fight the flu virus in infected individuals by inhibiting neuraminidase, a flu protein responsible for the release of newly synthesized virions. However, oseltamivir resistance has become a critical problem due to rapid mutation of the flu virus. Unfortunately, how mutations actually confer drug resistance is not well u...

Journal: :The Journal of infectious diseases 2009
Yacine Abed Mariana Baz Guy Boivin

Neuraminidase (NA) mutations responsible for influenza resistance to oseltamivir vary according to the NA subtype; in influenza A/H3N2 viruses, NA-gene mutations occur predominantly at codons E119 and R292. In an oseltamivir-resistant influenza A/H3N2 virus isolated from an immunocompromised child after 107 days of cumulative treatment, the NA gene contained 3 aa substitutions (N146K, S219T, an...

2015
Sang Won Jeon Changsu Han

Oseltamivir is the most common antiviral drug used to treat and prevent influenza. Epidemiological studies performed in Japan, the United States, and the United Kingdom indicate that oseltamivir may cause psychiatric symptoms; however, the underlying mechanism has not been elucidated. In South Korea, interest in oseltamivir has increased with the spread of the new influenza virus; however, no c...

2011
Seung-Dok Hong Seong-Hwan Park Seung-Ji Kang Yong Soo Kwon Seung-Jung Kee Kyung-Hwa Park Sook-In Jung Hee-Chang Jang

It has been suggested that oseltamivir-resistant influenza viruses harboring the H274/275Y mutation are less virulent than are those that are oseltamivir-sensitive, and fatality attributed to infection with an oseltamivir-resistant virus is very rare. Here we report the first fatal adult case of oseltamivir-resistant 2009 pandemic influenza A (H1N1) in Korea. A 60-year-old Korean male who had h...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید